Germie van den Dobbelsteen, PhD

Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Netherlands

Disclosure(s): Janssen: Employee of Janssen Vaccines & Prevention B.V., Stocks/Bonds

Poster(s):

• 120 - Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET